Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Amyloid Fibril Components Exhibit Distinct Molecular Recycling Properties

By LabMedica International staff writers
Posted on 15 Jun 2011
A publication revealed that the protein fragments comprising amyloid fibrils - abnormal strands of protein associated with some two dozen diseases ranging from Alzheimer's to type-2 diabetes – undergo a continuous cycle of dissociation and reassociation.

Previously NMR-guided simulations had shown that the two fragments, amyloid-beta-40 and amyloid-beta-42, seemed to feature highly different conformational states, with the C-terminus of amyloid-beta-42 being more structured than that of the amyloid-beta-40 fragment. More...
Now, in a paper published in the April 12, 2011, online edition of the Journal of the American Chemical Society investigators at the Institute for Research in Biomedicine (Barcelona, Spain) analyzed the movement of protein fragments within amyloid fibrils.

The investigators used an advanced technique called electrospray ionization mass spectrometry to monitor hydrogen/deuterium exchange in amyloid-beta-fibrils. They found after monitoring recycling for 40 days that both amyloid-beta-40 and amyloid-beta-42 molecules recycled within the fibril population, although to different extents. After 40 days, 80% of the molecules making up amyloid-beta-40 fibrils underwent recycling while only 30% did so in amyloid-beta-42 fibrils. These observations imply that amyloid-beta-42 recycled more slowly, which has implications for understanding the role of amyloid-beta-fibrils in neurotoxicity and for designing therapeutic strategies against Alzheimer's disease.

"In the context of Alzheimer's disease, demonstrating that recycling occurs in the fibrils is a step forward but it is also crucial to identify the recycling species involved; whether they are individual amyloid-beta units or small aggregates made of several units," said senior author Dr. Natalia Carulla, professor of chemistry at the Institute for Research in Biomedicine. "It will be important to address if differences in the recycling species within amyloid-beta-40 and amyloid-beta-42 fibrils are relevant in the development of Alzheimer's disease. We are now working towards this aim. Once we have this information, we will be in a position to devise new therapeutic strategies that can modulate recycling."

Related Links:
Institute for Research in Biomedicine


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.